We’re thrilled to share our enlightening exchange with Spiro Rombotis, the seasoned CEO of Cyclacel. He peels back the curtain on the breakthrough discovery of B53, a commonly mutated gene in cancer patients, and the inspiring success of FADRA, their lead drug in clinical trials. Furthermore, Spiro delves into the highs and lows faced by Cyclacel, including the triumphant moment a patient was declared cancer-free thanks to their groundbreaking drug.

First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.

Interested in being featured as a guest on First In Human? Please reach out to [email protected].

🎧 Stay in the Loop!

For the latest news and updates, visit our website: https://vial.com

Follow us on social media for real-time insights:

Twitter: https://twitter.com/VialTrials

LinkedIn: https://www.linkedin.com/company/vialtrials